Yes, Methotrexate Can Reduce Other Drugs' Effectiveness
Methotrexate, a folate antagonist used for rheumatoid arthritis, cancer, and psoriasis, inhibits dihydrofolate reductase, which can alter the metabolism, absorption, or action of co-administered drugs. This often happens through competition for transporters like OATs or BCRP, reduced renal clearance, or cytochrome P450 interactions.[1][2]
Common Drugs Affected and How
- Proton Pump Inhibitors (PPIs) like Omeprazole: Methotrexate clearance drops up to 90% with high-dose PPIs due to inhibited renal secretion, raising methotrexate toxicity and potentially blunting other drugs' effects indirectly via prolonged exposure.[3]
- NSAIDs (e.g., Ibuprofen, Naproxen): They compete for renal secretion, increasing methotrexate levels by 30-100%, which can diminish NSAID anti-inflammatory effects or amplify risks.[1][4]
- Antibiotics like Penicillins or Ciprofloxacin: Reduce methotrexate excretion, leading to higher levels that may counteract antibiotic efficacy in infections.[2]
- Antimalarials (e.g., Hydroxychloroquine): Additive folate antagonism can lessen each drug's standalone benefits in autoimmune conditions.[5]
Mechanisms Behind the Interactions
Methotrexate uses organic anion transporters (OAT1/3, OATPs) for uptake and efflux. Drugs blocking these—like probenecid or salicylates—trap methotrexate intracellularly, elevating plasma levels and altering downstream effects on other therapies.[1][6] Acidic environments from PPIs further impair tubular secretion.[3]
Risks of Reduced Effectiveness or Toxicity
High methotrexate levels from interactions increase risks like myelosuppression, mucositis, or renal failure, indirectly reducing the therapeutic window for partners like biologics (e.g., TNF inhibitors in RA).[4][7] Low-dose chronic use (e.g., 7.5-25 mg/week) sees milder effects, but monitoring is key.
How to Manage Interactions
- Space methotrexate from PPIs/NSAIDs by 12-24 hours.[3]
- Monitor levels during high-dose regimens with interacting drugs.[2]
- Folic acid supplementation (1-5 mg/day) mitigates some antagonism without fully resolving drug conflicts.[5]
- Tools like Lexicomp or FDA labels flag risks; consult pharmacists for polypharmacy.[1]
When Does This Matter Most?
Interactions peak with high-dose IV methotrexate (>500 mg/m2) in oncology, but low-dose oral use in RA affects 20-30% of patients on PPIs.[3][8] Genetic variants in transporters (e.g., SLCO1B1) amplify risks in some individuals.[6]
Sources
[1] FDA Methotrexate Label
[2] Drugs.com Interaction Checker
[3] AJHP Study on PPIs
[4] Arthritis Foundation Guidelines
[5] UpToDate: Methotrexate Interactions
[6] Pharmacogenomics Review
[7] NEJM Case Report
[8] Rheumatology Journal Analysis